NEW YORK (GenomeWeb) – DermTech announced on Monday that it has secured payor coverage for its pigmented lesion assay (PLA) from CareFirst Blue Cross/Blue Shield and its affiliate CareFirst BlueChoice.

The non-invasive assay is designed to analyze the expression of two oncogenes to differentiate malignant melanoma from benign pigmented skin lesions. DermTech said that CareFirst will now cover the test for its 3.4 million members, effective for claims for services performed on or after June 1.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.